Company Profile

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE599.70-16.7 (-2.71 % )
PREV CLOSE (Rs.) 616.40
OPEN PRICE (Rs.) 616.40
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 163820
TODAY'S LOW / HIGH (Rs.)590.95 617.60
52 WK LOW / HIGH (Rs.)251 723.55
NSE599.45 -17.55 (-2.84 % )
PREV CLOSE(Rs.) 617.00
OPEN PRICE (Rs.) 615.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 599.45 (482 )
VOLUME 2364834
TODAY'S LOW / HIGH(Rs.) 590.40 616.95
52 WK LOW / HIGH (Rs.)252 723.75

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.33
TTM EPS (Rs.) 19.00
P/E Ratio 31.57
Book Value (Rs.) 54.59
Face Value (Rs.) 2
MCap (Rs. in Mn) 321800.45
Price/Earning (TTM) 26.29
Price/Sales (TTM) 6.41
Price/Book (MRQ) 10.99
PAT Margin (%) 20.05
ROCE (%) 38.60
Incorporation Year : 2005

Management Info :

M Venu Gopala Rao - Chairman - Managing Director

Registered Office :

Address : Plot No.21, J N Pharma City,Parawada, ,
Vishakhapatnam,
Andhra Pradesh-531021

Phone : 0891 3061222

Website : www.lauruslabs.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
20Oct10-20-2021$Laurus Labs informs about board meeting Laurus Labs informs about bo
Laurus Labs has informed that the meeting of the Board of Directors of the Company is scheduled on 28/10/2021 to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2021; to consider the proposal for payment of Interim Dividend for FY 2021-22 and fixation of record date for determining the eligibility of shareholders (if approved).

The above information is a part of company’s filings submitted to BSE.

Laurus Labs has informed that the meeting of the Board of Direc..
11Oct10-11-2021$Laurus Labs informs about certificate Laurus Labs informs about ce

In accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 and based on the certificates received from KFin Technologies (Registrar and Share Transfer Agent), Laurus Labs has confirmed that no requests received from depository participants for dematerialization of securities during the quarter ended September 30, 2021.

The above information is a part of company’s filings submitted to BSE.

In accordance with Regulation 74(5) of the SEBI (Depositories a..
15Sep09-15-2021$ Announcement under Regulation 30 (LODR)-Press Release / Media Release Announcement under Regulati
The Company is pleased to announce that development is underway based on an agreement launched in June 2021 between the Company, Unitaid and the Clinton Health Access Initiative (CHAI), to accelerate the development, commercialization, and registration of the best-in-class second- and third-line HIV treatment darunavir boosted with ritonavir (DRV/r) for children. Despite being available in high-income countries for over a 15-year period, a generic, fixed-dose combination pediatric version of DRV/r is still not available. Through this agreement, Unitaid and CHAI are working with the Company to finally address this critical need and ensure CLHIV (Children Living with HIV/AIDS) have access to high-quality second- and third-line HIV treatment.
The Company is pleased to announce that development is underway..
14Sep09-14-2021$Laurus Labs developing third-line HIV treatment for children Laurus Labs developing third

Laurus Labs is developing a third-line HIV treatment, darunavir boosted with ritonavir (DRV/r), for children. The development is under way based on an agreement inked in June 2021 by the Hyderabad-based company, Unitaid and the Clinton Health Access Initiative (CHAI).

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs is developing a third-line HIV treatment, darunavir..
14Sep09-14-2021$Laurus Labs informs about press release Laurus Labs informs about pr

Laurus Labs has informed that development is underway based on an agreement launched in June 2021 between the Company, Unitaid and the Clinton Health Access Initiative (CHAI), to accelerate the development, commercialization, and registration of the best-in-class second- and third-line HIV treatment darunavir boosted with ritonavir (DRV/r) for children. Despite being available in high-income countries for over a 15-year period, a generic, fixed-dose combination pediatric version of DRV/r is still not available. Through this agreement, Unitaid and CHAI are working with the Company to finally address this critical need and ensure CLHIV (Children Living with HIV/AIDS) have access to high-quality second- and third-line HIV treatment. A press release to this extent is also enclosed for information and records.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs has informed that development is underway based on..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit2220.89561.1
Gross Profit 2901 12746.3
Operating Profit 3706.315371.9
Net Sales 1220647687.2
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20746.95 (0.93%)
M.Cap ( in Cr)
44085.82
Ajanta Pharma (BSE)
 2215.40 (2.45%)
M.Cap ( in Cr)
19171.13
Sanofi India (BSE)
 8117.95 (0.35%)
M.Cap ( in Cr)
18696.14
Mercury Laboratories (BSE)
 718.00 (3.16%)
M.Cap ( in Cr)
86.16
Suven Pharma (BSE)
 533.95 (1.75%)
M.Cap ( in Cr)
13592.50
Shareholding Pattern More
NON-INSTITUTION 45.06 %
PROMOTERS 27.3 %
MUTUAL FUNDS/UTI 2.08 %
FII 0.04 %
FI/BANKS/INSURANCE 0.03 %
GOVERNMENT 0 %
F & O Quotes